SCHEMBL22010185

SCHEMBL22010185

COCC(=O)C1CN(Cc2ccccc2)CC1(F)F

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.48
CYP2D6 P10635 6/20 0.47
CYP3A4 P08684 2/20 0.47
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
GHSR Q92847 1/20 0.42
OPRM1 P35372 2/20 0.41
SIGMAR1 Q99720 2/20 0.41
NR1H2 P55055 1/20 0.40
S1PR1 P21453 1/20 0.40
S1PR5 Q9H228 1/20 0.40
GAA P10253 1/20 0.40
FUCA1 P04066 2/20 0.38
ARG1 P05089 1/20 0.38
ARG2 P78540 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17499930 0.83 S1PR5 (0.50) TSHRCYP2D6ALDH1A1MEN1LMNA
SCHEMBL29287890 0.83 S1PR5 (0.50) TSHRCYP2D6ALDH1A1MEN1LMNA
SCHEMBL17517700 0.80 L3MBTL1 (0.48) CYP2D6CYP3A4ALDH1A1MEN1KMT2A
SCHEMBL20179770 0.75 L3MBTL1 (0.46) CYP2D6ALDH1A1S1PR1S1PR5FUCA1
SCHEMBL20179769 0.72 ALDH1A1 (0.45) TSHRCYP2D6CYP3A4ALDH1A1SIGMAR1
SCHEMBL16714529 0.72 FUCA1 (0.53) TSHRALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL26009111 0.72 ACHE (0.49) TSHRCYP2D6MEN1LMNAKMT2A
SCHEMBL15647532 0.72 DRD4 (0.48) TSHRCYP2D6CYP3A4ALDH1A1MEN1
SCHEMBL29797081 0.72 ALDH1A1 (0.56) TSHRCYP2D6CYP3A4ALDH1A1MEN1
SCHEMBL28554966 0.72 S1PR5 (0.45) TSHRCYP2D6CYP3A4ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10662203-B2 Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection HOFFMANN-LA ROCHE INC. (US) 2020-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662203-B2 Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection IDO1, IDO2, KYNU TSHR 1054/4885CYP2D6 64/4885CYP3A4 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.